Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last A$3.63 AUD
Change Today 0.00 / 0.00%
Volume 366.3K
MSB On Other Exchanges
As of 11:17 PM 03/31/15 All times are local (Market data is delayed by at least 15 minutes).

mesoblast ltd (MSB) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/3/14 - A$5.88
52 Week Low
03/26/15 - A$3.50
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MESOBLAST LTD (MSB)

Related News

No related news articles were found.

mesoblast ltd (MSB) Details

Mesoblast Limited, a biotechnology company, is engaged in the research and development of its propriety stem cell technologies for use in the treatment of multiple major disease states and other medical conditions. The company’s cell-based core technologies include immunoselected mesenchymal precursor cells (MPCs), culture-expanded mesenchymal stem cells (MSCs), dental pulp stem cells, and expanded hematopoietic stem cells. Its lead products include MSC-100-IV, which is used for the treatment of steroid refractory acute graft versus host disease and biologic refractory crohn’s disease; MPC-06-ID that is used for the treatment of chronic low back pain; and MPC-150-IM, which is used for congestive heart failure treatment. The company also offers supporting products, such as MPC-300-IV, an intravenously administered MPCs that are used for the treatment of type 2 diabetes, liver/kidney complications, and rheumatoid arthritis; MPC-25-IC, which is used for the treatment of acute myocardial infarction; MPC-25-Osteo for use in surgical bone repair; MPC-CBE that is used in bone marrow transplantations; and MPC-MICRO-IO for use in age-related macular degeneration treatment. In addition, it provides various products for the treatment of ophthalmology diseases, neurological diseases, lung diseases, etc. The company has strategic alliances with Lonza Group for clinical and long-term commercial production of its off-the-shelf (allogeneic) adult stem cell products; and Teva Pharmaceutical Industries Ltd. for the development and commercialization of its immunoselected MPCs that are used for cardiac and vascular diseases. It has operations in Australia, the United States, and Singapore. Mesoblast Limited was founded in 2004 and is headquartered in Melbourne, Australia.

115 Employees
Last Reported Date: 08/25/14
Founded in 2004

mesoblast ltd (MSB) Top Compensated Officers

Founder, Chairman of Scientific Advisory Boar...
Total Annual Compensation: A$1.8M
Compensation as of Fiscal Year 2014.

mesoblast ltd (MSB) Key Developments

Japan External Trade Organization Selects Mesoblast Limited for Fast Track Access to Potential Investment Incentives in Japan

Mesoblast Limited announced that it has been selected by the Japan External Trade Organization as the only regenerative medicine company worldwide to receive fast track access to potential investment incentives across all levels of government in Japan. Mesoblast will receive a specially tailored market and government incentive roadmap aimed at providing a more attractive business environment. Ten companies across all industries, including Mesoblast, were chosen to receive fast track access to specific incentives and programs.

Mesoblast Limited, H1 2015 Earnings Call, Feb 12, 2015

Mesoblast Limited, H1 2015 Earnings Call, Feb 12, 2015

Mesoblast Limited Announces Earnings Results for the Half Year Ended December 31, 2014

Mesoblast Limited announced earnings results for the half year ended December 31, 2014. For the period, the company's total revenue from continuing operations and other income was AUD 25.9 million, an increase of AUD 5.1 million on the previous corresponding half-year period, primarily due to foreign exchange gains and a milestone payment received from Japanese partner, JCR Pharmaceuticals Co. Ltd. (JCR), on its submission of JR-031 for marketing approval to the Japanese Regulatory Authority. Net operating cash outflow was AUD 56.5 million, compared with outflows of AUD 48.0 million during the previous corresponding half-year period, driven primarily by increased spend on company's Tier 1 and Tier 2 clinical programs. The company reported a net loss of AUD 50.8 million, principally due to an increase of AUD 10.8 million in cash expenditure related to progress in the clinical programs, and AUD 10.7 million increase in contingent consideration pertaining to the acquisition of culture-expanded MSC assets. Revenue from continuing operations was AUD 12.9 million against AUD 13.9 million a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MSB:AU A$3.63 AUD 0.00

MSB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Athersys Inc $2.88 USD +0.02
BioTime Inc $4.97 USD -0.03
Ocata Therapeutics Inc $6.16 USD +0.03
Osiris Therapeutics Inc $17.58 USD -0.07
Pluristem Therapeutics Inc $2.80 USD -0.04
View Industry Companies

Industry Analysis


Industry Average

Valuation MSB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 34.5x
Price/Book 1.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 30.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MESOBLAST LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at